Lilly's Carroll: Let's Debate Pricing But Don't Lump Us With Turing
This article was originally published in Scrip
Executive Summary
At the recent BIO-Europe meeting, held in Munich, Germany, Eli Lilly & Co's senior vice president of corporate business development Darren Carroll, in an exclusive interview with Scrip, highlighted his expectations for 2016 and concerns for innovative pharmaceutical companies being tarred with the same brush as current businesses which are under the spotlight for unfounded soaring drug prices in the US.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.